| Authors: |
Gloeckl R; Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Schoenau am Koenigssee, Germany, Tal-Singer R; Global Allergy and Airways Patient Platform, Vienna, Austria, Deussen P; Biomedical Research Group Oxford (PPI), Oxford, United Kingdom, Winwood R; Inogen Global, Zurich, Switzerland; COPD Baton Pass, Salisbury, United Kingdom, Mohan T; Global Medical Affairs, General Medicines, GSK, London, United Kingdom, Turner M; Global Clinical Operations Research and Development, GSK, Collegeville, Pennsylvania, United States, Hamouda M; Value Evidence and Outcomes Research, GSK, Dubai, United Arab Emirates, Moore M; Global Medical Affairs, General Medicines, GSK, London, United Kingdom, Jones P; Advanced Pipeline Unit Respiratory, GSK, London, United Kingdom; Institute of Infection and Immunity, City St George’s, University of London, London, United Kingdom |
